Akorn (OTCMKTS: ELGXQ) is one of 143 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Akorn to similar businesses based on the strength of its earnings, risk, dividends, institutional ownership, valuation, analyst recommendations and profitability.

Institutional and Insider Ownership

48.3% of Akorn shares are owned by institutional investors. Comparatively, 46.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 1.3% of Akorn shares are owned by company insiders. Comparatively, 15.0% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Akorn has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Akorn’s rivals have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Akorn and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akorn 0 0 0 0 N/A
Akorn Competitors 1312 4167 6848 396 2.50

As a group, “Surgical & medical instruments” companies have a potential upside of 11.58%. Given Akorn’s rivals higher possible upside, analysts clearly believe Akorn has less favorable growth aspects than its rivals.

Profitability

This table compares Akorn and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akorn -47.89% -113.17% -20.37%
Akorn Competitors -609.75% -71.50% -19.94%

Valuation & Earnings

This table compares Akorn and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Akorn $143.37 million -$64.76 million -0.02
Akorn Competitors $1.35 billion $138.57 million -6.76

Akorn’s rivals have higher revenue and earnings than Akorn. Akorn is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Akorn rivals beat Akorn on 7 of the 10 factors compared.

About Akorn

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. On July 5, 2020, Endologix, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with TriVascular Sales LLC.

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.